Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Anti-VEGF Agents and the Risk of Arteriothrombotic Events

Anti-VEGF Agents and the Risk of Arteriothrombotic Events Downloaded from http://journals.lww.com/apjoo by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/04/2020 REVIEW ARTICLE Anti-VEGF Agents and the Risk of Arteriothrombotic Events Marco A. Zarbin, MD, PhD, FACS 33% of patients receiving systemic anti-VEGF therapy for cancer. Abstract: Blockade of vascular endothelial growth factor (VEGF) sig- Vascular endothelial death results in exposure of procoagulant naling, whether via sequestration of free VEGF or via inhibition of the phospholipids on the luminal plasma membrane and underlying tyrosine kinases activated by VEGF, is associated with decreased nitric extracellular matrix and a tendency for thrombosis [eg, cerebro- oxide (NO) and prostaglandin-I 2 (PG-I 2) production along with vascular vascular accident (CVA), myocardial infarction (MI), transient endothelial cell death. Systemic administration of drugs that block VEGF ischemic attack (TIA), or subarachnoid hemorrhage], which oc- signaling (eg, for cancer treatment) is associated with systemic complica- curs in approximately 4% of patients receiving systemic anti- tions such as hypertension and thrombosis. Evidence regarding the risk of VEGF therapy for cancer. systemic serious adverse events after intravitreal injection of anti-VEGF agents in patients with diabetic macular edema or neovascular age-relat- ed macular degeneration is inconsistent, in part because of study design SyStemic RiSkS ASSociAted With limitations (eg, bias of ascertainment through strict http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Asia-Pacific Journal of Ophthalmology Wolters Kluwer Health

Anti-VEGF Agents and the Risk of Arteriothrombotic Events

Loading next page...
 
/lp/wolters-kluwer-health/anti-vegf-agents-and-the-risk-of-arteriothrombotic-events-qCLoA4XvAP
Publisher
Wolters Kluwer Health
ISSN
2162-0989
eISSN
2475-5028
DOI
10.22608/APO.2017495
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/apjoo by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/04/2020 REVIEW ARTICLE Anti-VEGF Agents and the Risk of Arteriothrombotic Events Marco A. Zarbin, MD, PhD, FACS 33% of patients receiving systemic anti-VEGF therapy for cancer. Abstract: Blockade of vascular endothelial growth factor (VEGF) sig- Vascular endothelial death results in exposure of procoagulant naling, whether via sequestration of free VEGF or via inhibition of the phospholipids on the luminal plasma membrane and underlying tyrosine kinases activated by VEGF, is associated with decreased nitric extracellular matrix and a tendency for thrombosis [eg, cerebro- oxide (NO) and prostaglandin-I 2 (PG-I 2) production along with vascular vascular accident (CVA), myocardial infarction (MI), transient endothelial cell death. Systemic administration of drugs that block VEGF ischemic attack (TIA), or subarachnoid hemorrhage], which oc- signaling (eg, for cancer treatment) is associated with systemic complica- curs in approximately 4% of patients receiving systemic anti- tions such as hypertension and thrombosis. Evidence regarding the risk of VEGF therapy for cancer. systemic serious adverse events after intravitreal injection of anti-VEGF agents in patients with diabetic macular edema or neovascular age-relat- ed macular degeneration is inconsistent, in part because of study design SyStemic RiSkS ASSociAted With limitations (eg, bias of ascertainment through strict

Journal

The Asia-Pacific Journal of OphthalmologyWolters Kluwer Health

Published: Jan 1, 2018

There are no references for this article.